Sartorius Stedim Biotech (0RG8) Share Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0RG8 Analyst Ratings

Moderate Buy

5 Buy

2 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Sartorius

Stedim Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0RG8 Stock 12 Month Forecast

Average Price Target

€233.57

▲(13.79% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Sartorius Stedim Biotech in the last 3 months. The average price target is €233.57 with a high forecast of €260.00 and a low forecast of €210.00. The average price target represents a 13.79% change from the last price of €205.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"170":"€170","261":"€261","192.75":"€192.8","215.5":"€215.5","238.25":"€238.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":260,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€260.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":233.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€233.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":210,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€210.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[170,192.75,215.5,238.25,261],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,208.1,212.09230769230768,216.08461538461538,220.07692307692307,224.06923076923076,228.06153846153845,232.05384615384617,236.04615384615386,240.03846153846155,244.03076923076924,248.02307692307693,252.01538461538462,256.0076923076923,{"y":260,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,208.1,210.05923076923077,212.01846153846154,213.9776923076923,215.93692307692308,217.89615384615385,219.8553846153846,221.81461538461537,223.77384615384614,225.7330769230769,227.69230769230768,229.65153846153845,231.61076923076922,{"y":233.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,208.1,208.24615384615385,208.3923076923077,208.53846153846155,208.68461538461537,208.83076923076922,208.97692307692307,209.12307692307692,209.26923076923077,209.41538461538462,209.56153846153845,209.7076923076923,209.85384615384615,{"y":210,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":172.3,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.92,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":208.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€260.00

Average Price Target€233.57

Lowest Price Target€210.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Vosser

J.P. Morgan

€225→€260

Buy

26.66%

Upside

Reiterated

12/08/25

J.P. Morgan Keeps Their Buy Rating on Sartorius Stedim Biotech (0RG8)

Charles Weston

RBC Capital

€230→€240

Buy

16.92%

Upside

Reiterated

10/22/25

RBC Capital Keeps Their Buy Rating on Sartorius Stedim Biotech (0RG8)

Charles Pitman CFA

Barclays

€240→€230

Buy

12.05%

Upside

Reiterated

10/20/25

Barclays Remains a Buy on Sartorius Stedim Biotech (0RG8)

James Quigley

Goldman Sachs

€224→€246

Buy

19.84%

Upside

Reiterated

10/20/25

Goldman Sachs Sticks to Their Buy Rating for Sartorius Stedim Biotech (0RG8)

James Vane

Jefferies

€229

Buy

11.56%

Upside

Reiterated

10/16/25

Sartorius Stedim Biotech (0RG8) Receives a Buy from Jefferies

Oliver Reinberg

Kepler Capital

€210

Hold

2.30%

Upside

Reiterated

10/16/25

Kepler Capital Keeps Their Hold Rating on Sartorius Stedim Biotech (0RG8)

Matthew Weston

UBS

€220

Hold

7.18%

Upside

Reiterated

10/10/25

UBS Sticks to Its Hold Rating for Sartorius Stedim Biotech (0RG8)

Odysseas Manesiotis

Exane BNP Paribas

€233

Buy

13.51%

Upside

Initiated

05/29/25

Sartorius Stedim Biotech (0RG8) Receives a New Rating from Exane BNP Paribas

Thibault Boutherin

Morgan Stanley

€260→€250

Buy

21.79%

Upside

Reiterated

04/22/25

Sartorius Stedim Biotech (DIM:FP) (SDMHF) PT Lowered to EUR250 at Morgan StanleyMorgan Stanley analyst Thibault Boutherin lowered the price target on Sartorius Stedim Biotech (DIM:FP) (OTC: SDMHF) to EUR250.00 (from EUR260.00) while maintaining a Overweight rating.

Delphine Le Louet

Bernstein

€234

Hold

14.00%

Upside

Reiterated

04/16/25

Sartorius Stedim Biotech (0RG8) Gets a Hold from Bernstein

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Vosser

J.P. Morgan

€225→€260

Buy

26.66%

Upside

Reiterated

12/08/25

J.P. Morgan Keeps Their Buy Rating on Sartorius Stedim Biotech (0RG8)

Charles Weston

RBC Capital

€230→€240

Buy

16.92%

Upside

Reiterated

10/22/25

RBC Capital Keeps Their Buy Rating on Sartorius Stedim Biotech (0RG8)

Charles Pitman CFA

Barclays

€240→€230

Buy

12.05%

Upside

Reiterated

10/20/25

Barclays Remains a Buy on Sartorius Stedim Biotech (0RG8)

James Quigley

Goldman Sachs

€224→€246

Buy

19.84%

Upside

Reiterated

10/20/25

Goldman Sachs Sticks to Their Buy Rating for Sartorius Stedim Biotech (0RG8)

James Vane

Jefferies

€229

Buy

11.56%

Upside

Reiterated

10/16/25

Sartorius Stedim Biotech (0RG8) Receives a Buy from Jefferies

Oliver Reinberg

Kepler Capital

€210

Hold

2.30%

Upside

Reiterated

10/16/25

Kepler Capital Keeps Their Hold Rating on Sartorius Stedim Biotech (0RG8)

Matthew Weston

UBS

€220

Hold

7.18%

Upside

Reiterated

10/10/25

UBS Sticks to Its Hold Rating for Sartorius Stedim Biotech (0RG8)

Odysseas Manesiotis

Exane BNP Paribas

€233

Buy

13.51%

Upside

Initiated

05/29/25

Sartorius Stedim Biotech (0RG8) Receives a New Rating from Exane BNP Paribas

Thibault Boutherin

Morgan Stanley

€260→€250

Buy

21.79%

Upside

Reiterated

04/22/25

Delphine Le Louet

Bernstein

€234

Hold

14.00%

Upside

Reiterated

04/16/25

Sartorius Stedim Biotech (0RG8) Gets a Hold from Bernstein

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sartorius Stedim Biotech

1 Month

xxx

Success Rate

11/20 ratings generated profit

Average Return

+2.99%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.00% of your transactions generating a profit, with an average return of +2.99% per trade.

3 Months

xxx

Success Rate

11/20 ratings generated profit

Average Return

+1.63%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.00% of your transactions generating a profit, with an average return of +1.63% per trade.

1 Year

James VaneJefferies

Success Rate

6/11 ratings generated profit

Average Return

-3.36%

reiterated a buy rating 2 months ago

Copying James Vane's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of -3.36% per trade.

2 Years

xxx

Success Rate

7/11 ratings generated profit

Average Return

-0.10%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of -0.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0RG8 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0RG8 has received 8 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. 0RG8 average Analyst price target in the past 3 months is 233.57.

Each month's total comprises the sum of three months' worth of ratings.

0RG8 Financial Forecast

0RG8 Earnings Forecast

Next quarter’s earnings estimate for 0RG8 is €1.24 with a range of €1.19 to €1.32. The previous quarter’s EPS was €0.94. 0RG8 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 0RG8 has Performed in-line its overall industry.

0RG8 Sales Forecast

Next quarter’s sales forecast for 0RG8 is €767.86M with a range of €755.21M to €779.94M. The previous quarter’s sales results were €705.70M. 0RG8 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 0RG8 has Performed in-line its overall industry.

0RG8 Stock Forecast FAQ

What is GB:0RG8’s average 12-month price target, according to analysts?

Based on analyst ratings, Sartorius Stedim Biotech’s 12-month average price target is 233.57.

What is GB:0RG8’s upside potential, based on the analysts’ average price target?

Sartorius Stedim Biotech has 13.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sartorius Stedim Biotech a Buy, Sell or Hold?

Sartorius Stedim Biotech has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 2 hold ratings and 0 sell ratings.

What is Sartorius Stedim Biotech’s share price target?

The average share price target for Sartorius Stedim Biotech is 233.57. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €260.00 ,and the lowest forecast is €210.00. The average share price target represents 13.79% Increase from the current price of €205.27.

What do analysts say about Sartorius Stedim Biotech?

Sartorius Stedim Biotech’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Sartorius Stedim Biotech?

To buy shares of GB:0RG8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Sartorius Stedim Biotech (0RG8) Share Forecast & Price Target

0RG8 Analyst Ratings

0RG8 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sartorius Stedim Biotech

0RG8 Analyst Recommendation Trends

0RG8 Financial Forecast

0RG8 Earnings Forecast

0RG8 Sales Forecast

0RG8 Stock Forecast FAQ

Detailed List of Analyst Forecasts